🚀 VC round data is live in beta, check it out!
GC Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for GC Biopharma and similar public comparables like AIM Vaccine, 4D Molecular Therapeutics, Aquestive Therapeutics, Synmosa Biopharma and more.
GC Biopharma Overview
About GC Biopharma
Green Cross Holdings Corp manufactures and sells medicines and medical supplies. The company's products include Plasma Derivatives, Vaccines, Prescription Drugs and Over-the-counter Drugs. Some of the drugs offered by the company comprise of Acustop Cataplasma, Zenol Cool Type, Green-VIII inj and Hunterase.
Founded
1967
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$1B
GC Biopharma Financials
GC Biopharma reported last fiscal year revenue of $1B and EBITDA of $142M.
In the same fiscal year, GC Biopharma generated $413M in gross profit, $142M in EBITDA, and $16M in net income.
GC Biopharma P&L
In the most recent fiscal year, GC Biopharma reported revenue of $1B and EBITDA of $142M.
GC Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $413M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 28% | XXX | XXX | XXX |
| EBITDA | — | XXX | $142M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1%) | XXX | XXX | XXX |
| Net Profit | — | XXX | $16M | XXX | XXX | XXX |
| Net Margin | — | XXX | 1% | XXX | XXX | XXX |
| Net Debt | — | — | $674M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GC Biopharma Stock Performance
GC Biopharma has current market cap of $493M, and enterprise value of $1B.
Market Cap Evolution
GC Biopharma's stock price is $10.90.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $493M | 0.0% | XXX | XXX | XXX | $0.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGC Biopharma Valuation Multiples
GC Biopharma trades at 1.0x EV/Revenue multiple, and 10.4x EV/EBITDA.
GC Biopharma Financial Valuation Multiples
As of March 17, 2026, GC Biopharma has market cap of $493M and EV of $1B.
Equity research analysts estimate GC Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GC Biopharma has a P/E ratio of 30.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $493M | XXX | $493M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (205.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.6x | XXX | XXX | XXX |
| P/E | — | XXX | 30.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (14.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GC Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GC Biopharma Margins & Growth Rates
GC Biopharma's revenue in the last fiscal year grew by 7%.
GC Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 218% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GC Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AIM Vaccine | XXX | XXX | XXX | XXX | XXX | XXX |
| 4D Molecular Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aquestive Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Synmosa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Climb Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GC Biopharma M&A Activity
GC Biopharma acquired XXX companies to date.
Last acquisition by GC Biopharma was on XXXXXXXX, XXXXX. GC Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GC Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGC Biopharma Investment Activity
GC Biopharma invested in XXX companies to date.
GC Biopharma made its latest investment on XXXXXXXX, XXXXX. GC Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GC Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GC Biopharma
| When was GC Biopharma founded? | GC Biopharma was founded in 1967. |
| Where is GC Biopharma headquartered? | GC Biopharma is headquartered in South Korea. |
| Who is the CEO of GC Biopharma? | GC Biopharma's CEO is Il-Seop Heo. |
| Is GC Biopharma publicly listed? | Yes, GC Biopharma is a public company listed on Korea Exchange. |
| What is the stock symbol of GC Biopharma? | GC Biopharma trades under 005250 ticker. |
| When did GC Biopharma go public? | GC Biopharma went public in 1978. |
| Who are competitors of GC Biopharma? | GC Biopharma main competitors are AIM Vaccine, 4D Molecular Therapeutics, Aquestive Therapeutics, Synmosa Biopharma. |
| What is the current market cap of GC Biopharma? | GC Biopharma's current market cap is $493M. |
| What is the current revenue of GC Biopharma? | GC Biopharma's last fiscal year revenue is $1B. |
| What is the current EV/Revenue multiple of GC Biopharma? | Current revenue multiple of GC Biopharma is 1.0x. |
| Is GC Biopharma profitable? | No, GC Biopharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.